TissueNetix CND™ Technology

The pressure to create safe, targeted & effective ethical drugs within the pharmaceutical industry has never been higher. Current toxicology assays often use rodent cell models, which offer poor predictive value. U.S. regulatory agencies have been clear that a more effective model is needed to predict drug response and toxicity. A few recent publications are shown here:

Despite significant progress in the drug screening process, cardiac toxicity is responsible for a remarkable 25% of late stage drug failures. In many cases, these failures occur after millions of dollars of testing, development, and clinical trial work.

CND offers the pharmaceutical industry the ability to accurately predict cardiac toxicity early in the development process, a potential savings of millions of dollars in development costs.  The technology is applicable to neuronal, liver, kidney, and other tissue/organ based models. Using human IPSC cell lines that behave as tissue, CND creates a new standard for compound toxicity evaluation.

Latest News

New Company Formed for Development of new cardiac toxicity assays

San Diego, Calif., November 12, 2011 – Three entrepreneurs have joined to form a new company called TissueNetix, Inc., based in San Diego, CA.  The long-term goal of TissueNetix is to develop high-throughput assays based on human cellular networks.  The first assay that the company is targeting will detect compounds in the drug discovery process that have cardiac toxicity.  The founders are David Giegel, Ph.D., Roberta Gottlieb, M.D., and Lewis Shuster, M.B.A.

Go to top